Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Sponsor: Vir Biotechnology, Inc.
Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Official title: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2025-03-12
Completion Date
2031-05
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
Tobevibart
Tobevibart administered by subcutaneous injection
Elebsiran
Elebsiran administered by subcutaneous injection
Locations (39)
Investigative Site
Chandler, Arizona, United States
Investigative Site
Los Angeles, California, United States
Investigative Site
Redwood City, California, United States
Investigative Site
San Francisco, California, United States
Investigative Site
DeLand, Florida, United States
Investigative Site
Chicago, Illinois, United States
Investigative Site
Baltimore, Maryland, United States
Investigative Site
Hillsborough, New Jersey, United States
Investigative Site
New York, New York, United States
Investigative Site
New York, New York, United States
Investigative Site
New York, New York, United States
Investigative Site
Murray, Utah, United States
Investigative Site
Seattle, Washington, United States
Investigative Site
Calgary, Alberta, Canada
Investigative Site
Montreal, Quebec, Canada
Investigative Site
Montreal, Canada
Investigative Site
Ottawa, Canada
Investigative Site
Québec, Canada
Investigative Site
Vancouver, Canada
Investigative Site
Tbilisi, Georgia
Investigative Site
Tbilisi, Georgia
Investigative Site
Tbilisi, Georgia
Investigative Site
Frankfurt, Germany
Investigative Site
Hanover, Germany
Investigative Site
Heidelberg, Germany
Investigative Site
Chisinau, Moldova
Investigative Site
Auckland, New Zealand
Investigative Site
Karachi, Pakistan
Investigative Site
Karachi, Pakistan
Investigative Site
Lahore, Pakistan
Investigative Site
Rawalpindi, Pakistan
Investigative Site
Bucharest, Romania
Investigative Site
Bucharest, Romania
Investigative Site
Bucharest, Romania
Investigative Site
Kyiv, Ukraine
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Investigative Site
Nottingham, United Kingdom